Skip to content

Multi-Center Registry Cohort Study on Prognostic Factors and Prediction Model Construction in Aneurysmal SAH

Multi-Center Registry Cohort Study on Prognostic Factors and Prediction Model Construction in Aneurysmal Subarachnoid Hemorrhage

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05738083
Acronym
PROSAH-MPC
Enrollment
5000
Registered
2023-02-21
Start date
2018-10-01
Completion date
2029-12-30
Last updated
2026-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aneurysmal Subarachnoid Hemorrhage

Brief summary

PROSAH-MPC, a collaborative research project among neurosurgical centers in China, focuses on aneurysmal subarachnoid hemorrhage (aSAH). Its aim is to identify prognostic factors and develop robust prediction models for complications, disability, and mortality in aSAH patients. By leveraging a large, multi-center, prospective cohort design, PROSAH-MPC aims to overcome limitations of past studies and provide a more comprehensive understanding of the disease.

Detailed description

PROSAH-MPC (Prognostic Factors and Prediction Models in Aneurysmal Subarachnoid Hemorrhage Multi-Center Prospective Cohort) is an ambitious research endeavor that brings together a consortium of neurosurgical centers across various regions to comprehensively investigate the complexities of aneurysmal subarachnoid hemorrhage (aSAH). This multi-faceted study aims to unlock the prognostic factors that underpin the outcomes of patients afflicted with this severe and often life-threatening cerebrovascular disorder. The primary objective of PROSAH-MPC is to construct and validate robust prediction models that can accurately forecast the risks of complications, disability, and mortality in aSAH patients. By leveraging the strengths of a large, multi-center, prospective cohort design, the study aims to overcome the limitations of previous single-center, limited sample size, or retrospective studies, enabling a more holistic and generalizable understanding of the disease. Central to the study is the collection of extensive clinical and radiological data from enrolled patients, including demographics, medical histories, treatment regimens, radiological features, and follow-up outcomes. Radiomic analysis of imaging data, such as CT and MRI scans, will be employed to extract subtle but crucial features that may predict patient outcomes by deep learning. This data-rich approach ensures that the prediction models are built on a solid foundation of evidence-based knowledge. PROSAH-MPC's ultimate goal is to transform the way we approach aSAH management by providing clinicians with reliable tools to assess individual patient risks and tailor treatment plans accordingly. The validated prediction models have the potential to enhance early recognition of high-risk patients, facilitate timely interventions, and ultimately improve patient outcomes and quality of life.

Interventions

DIAGNOSTIC_TESTMachine Leaning Models

Area Under the Curve (ROC): Measures the overall performance of the model across all classification thresholds. A higher AUC value indicates better performance. Accuracy: The proportion of correctly predicted outcomes (both positive and negative) out of all predictions made. Precision (Positive Predictive Value, PPV): The proportion of correctly predicted positive outcomes out of all predicted positive outcomes. Sensitivity (True Positive Rate, TPR): The proportion of actual positive outcomes that are correctly identified by the model. Specificity (True Negative Rate, TNR): The proportion of actual negative outcomes that are correctly identified by the model.

Sponsors

Second Affiliated Hospital of Nanchang University
Lead SponsorOTHER
Panzhihua Central Hospital
CollaboratorOTHER
Zhujiang Hospital
CollaboratorOTHER
Southwest Hospital, China
CollaboratorOTHER
Renmin Hospital of Wuhan University
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subarachnoid hemorrhage confirmed by computed tomography (CT); * Cerebral angiography (CTA) and digital subtraction angiography (DSA) examination confirming intracranial aneurysm rupture as the cause of the subarachnoid hemorrhage; * Blood routine, biochemical function, blood coagulation function, and craniocerebral CT performed within 24 hours of symptom onset; * Underwent aneurysm clipping by surgery or endovascular embolization within 72 hours after-onset.

Exclusion criteria

* Aneurysm rupture bleeding time exceeding 24 hours before hospital admission; * Incomplete image data or blood test information; * Long-term use of anticoagulant medications such as aspirin or warfarin; * Admitted to hospital with active infectious diseases; * long-term anticoagulant drugs such as aspirin, wave dimensions; * Presence of other intracranial vascular malformations.

Design outcomes

Primary

MeasureTime frameDescription
modified Rankin Scale (mRS) for evaluating the prognosis12 months post-eventA score of 3 or greater on the mRS indicates a poor prognosis, with significant disability or dependence on others for daily activities. A score less than 3 indicates a good prognosis, with the patient being able to live independently with minimal or no disability.
Delayed cerebral ischemia (DCI)30 days post-eventDCI is a common complication after aSAH and refers to a decline in neurological status or the presence of new infarctions on imaging, typically occurring days to weeks after the initial hemorrhage.

Secondary

MeasureTime frameDescription
Rebleeding30 days post-eventThis outcome measures the occurrence of recurrent intracranial hemorrhage from the same or another aneurysm within the study period.
Intracranial Aneurysm Re-Rupture30 days post-eventThis refers to the re-rupture of the aneurysm that caused the initial aSAH or the rupture of a different aneurysm.
Hydrocephalus30 days post-eventHydrocephalus is the abnormal accumulation of cerebrospinal fluid in the brain's ventricles, leading to their dilation.
Clearing Rate of Subarachnoid Hemorrhage14 days post-admission CT scanThis outcome measures the reduction in the volume of subarachnoid hemorrhage over time, quantified using BrainHemoAI software by comparing admission CT scans to subsequent scans (e.g., at discharge or follow-up).

Countries

China

Contacts

CONTACTXingen Zhu, Prof
zxg2008vip@163.com13803546020
CONTACTPing Hu, MD
hp666edu@163.com13207109734
STUDY_CHAIRXingen Zhu, Prof

Second Affiliated Hospital of Nanchang University

PRINCIPAL_INVESTIGATORQianxue Chen, Prof

Renmin Hospital of Wuhan University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 1, 2026